---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-171489"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2022-06-10T23:59:59+00:00"
generated_at: "2026-06-25T02:45:52.591464+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Cogent announces positive initial Phase 2 APEX data for bezuclastinib in advanced systemic mastocytosis

## Summary
- All 11 patients achieved ≥50% serum tryptase reduction; median reduction 89%.
- All 8 evaluable patients had ≥50% bone marrow mast cell reduction; six cleared aggregates.
- No periorbital/peripheral edema, cognitive effects, or intracranial bleeding reported.
- Two prior avapritinib patients showed similar benefit; all remained on study at cutoff.
- Company to accelerate timelines; next APEX update by end of 2022; SUMMIT data in H1 2023.

## SEC filing metadata
- accession: 0001193125-22-171489
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2022-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/0001193125-22-171489-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312522171489/d330856d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-171489
- JSON: https://secwatch.observer/filing/0001193125-22-171489.json
- Plain text: https://secwatch.observer/filing/0001193125-22-171489.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.